Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pharmather Holdings Ltd (OP:PHRRF)

0.0369 +0.0007 (+1.93%)

Delayed Quote Updated: 3:13 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	128,870
Open	0.0375
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0362
Today's Range	0.0360 - 0.0385
52wk Range	0.0322 - 0.2857
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform

Today 8:00 EDT

HighlightsPharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations,...

Via Newsfile

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

August 18, 2026

Marks the first milestone in PharmaTher's three-stage commercialization plan, advancing PERSONALIZ3D™ into early commercialization activitiesEstablishes the operating foundation to scale...

Via Newsfile

Performance

YTD	-50.1%	-50.1%
1 Month	-7.7%	-7.7%
3 Month	+5.4%	+5.4%
6 Month	-26.2%	-26.2%
1 Year	-86.2%	-86.2%

More News

PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing

August 11, 2026

Via Newsfile

PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides

July 29, 2026

Via Newsfile

PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations

July 27, 2026

Via Newsfile

PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval

July 21, 2026

Via Newsfile

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

July 15, 2026

Via Newsfile

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

May 27, 2026

Via Newsfile

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

May 13, 2026

Via Newsfile

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

April 21, 2026

Via Newsfile

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

April 20, 2026

Via Newsfile

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

April 16, 2026

Via Newsfile

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

April 13, 2026

Via Newsfile

PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

March 26, 2026

Via Newsfile

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

March 03, 2026

Via Newsfile

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

February 02, 2026

Via Newsfile

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

January 14, 2026

Via Newsfile

PharmaTher CEO Publishes Letter to Shareholders

January 02, 2026

Via Newsfile

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

December 02, 2025

Via Newsfile

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

November 17, 2025

Via Newsfile

PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

October 17, 2025

Via Newsfile

PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

October 16, 2025

Via Newsfile

PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

October 15, 2025

Via Newsfile

PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease

October 08, 2025

Via Newsfile

PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy

October 02, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Pharmather Holdings Ltd publicly traded?

Yes, Pharmather Holdings Ltd is publicly traded.

What exchange does Pharmather Holdings Ltd trade on?

Pharmather Holdings Ltd trades on the OTC Traded

What is the ticker symbol for Pharmather Holdings Ltd?

The ticker symbol for Pharmather Holdings Ltd is PHRRF on the OTC Traded

What is the current price of Pharmather Holdings Ltd?

The current price of Pharmather Holdings Ltd is 0.0369

When was Pharmather Holdings Ltd last traded?

The last trade of Pharmather Holdings Ltd was at 10/01/26 03:13 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.